A comparative study to determine the efficacy of topical Pirfenidone with Carbon dioxide laser versus Emollient with Carbon dioxide laser in the management of keloid

RESEARCH QUESTION:

Can topical Pirfenidone enhance the therapeutic outcomes of carbon dioxide laser treatment

in patients with keloids more effectively than standard emollient care with carbon dioxide

laser ?

AIMS AND OBJECTIVE:

• To evaluate the efficacy of topical Pirfenidone with CO2 laser therapy in keloid

• To evaluate the efficacy of emollient with CO2 laser therapy in keloids

• To compare the efficacy of efficacy of topical Pirfenidone with carbon dioxide laser vs

emollient with CO2 laser therapy in keloids

• To assess changes in scar characteristics using Detroit keloid scale

STUDY DESIGN:

Randomised Interventional Study

PLACE OF STUDY:

Outpatient department of Dermatology, Venereology & Leprosy, Acharya

Vinoba Bhave Rural Hospital**,**Sawangi Wardha

STUDY POPULATION:

Patients having keloid including both genders and >18 years of age, visiting to the department

of Dermatology, Venerology and Leprosy (DVL),Acharya Vinoba Bhave Rural Hospital,

Sawangi will be included in the study.

INCLUSION CRITERIA:

• Individuals aged more than 18 years

• Patients with clinically diagnosed keloid scars (confirmed by history and examination).

• Willingness to avoid other scar treatments during the study period.

• Ability to give written informed consent.

EXCLUSION CRITERIA:

• Active infection or ulceration over or around the keloid site

• History of keloid treatment within the past 3 months (e.g., steroid injections, laser,

cryotherapy).

• Patients on systemic steroids, immunosuppressants, or anticoagulants.

• Pregnant or lactating women.

• Known hypersensitivity or allergy to pirfenidone or laser procedures.

• History of hypertrophic scars (not true keloids) or other dermatological conditions

mimicking keloids.

• Patient with systemic diseases affecting wound healing (e.g., uncontrolled diabetes,

autoimmune disease).

• Patients with unrealistic expectations

• HIV, Hepatitis C, Hepatitis B positive patients